125545

The number most commonly refers to BLA 125545 , an FDA Biologics License Application for Retacrit (epoetin alfa-epbx) , which is a biosimilar to Epogen and Procrit used to treat anemia.

Below are draft social media posts tailored for different professional audiences based on this application: 125545

: Intravenous or subcutaneous, with IV recommended for hemodialysis patients. The number most commonly refers to BLA 125545

Biologics License Application (BLA) marks a significant milestone in expanding access to anemia treatments. As a biosimilar to US-licensed Epogen, Retacrit (epoetin alfa-epbx) provides a cost-effective alternative for treating anemia caused by chronic kidney disease, chemotherapy, or zidovudine in HIV-infected patients. Key highlights from the FDA review: 125545

📢